Protara Therapeutics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Protara Therapeutics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2014 | $2.95M | Mar 16, 2017 |
| FY2015 | Sep 30, 2014 | $2.95M | Mar 14, 2016 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($57.44M) | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | ($44.60M) | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | ($40.42M) | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | ($65.95M) | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | ($47.25M) | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | ($33.98M) | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | ($7.83M) | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | ($20.73M) | Mar 20, 2020 |
| FY2018 | Dec 31, 2017 | ($29.96M) | Mar 13, 2019 |
| FY2018 | Dec 31, 2016 | ($28.53M) | Mar 13, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($64.55M) | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | ($49.15M) | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | ($43.61M) | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | ($67.06M) | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | ($47.49M) | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | ($34.44M) | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | ($7.83M) | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | ($21.37M) | Mar 20, 2020 |
| FY2018 | Dec 31, 2017 | ($30.36M) | Mar 13, 2019 |
| FY2018 | Dec 31, 2016 | ($28.71M) | Mar 13, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $42.63M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $31.70M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $24.99M | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | $16.81M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $21.09M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $11.98M | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | $3.88M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $11.85M | Mar 20, 2020 |
| FY2018 | Dec 31, 2017 | $21.69M | Mar 13, 2019 |
| FY2018 | Dec 31, 2016 | $18.87M | Mar 13, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($56.37M) | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | ($35.81M) | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | ($37.56M) | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | ($26.46M) | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | ($34.50M) | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | ($23.41M) | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | ($5.01M) | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | ($23.23M) | Mar 20, 2020 |
| FY2018 | Dec 31, 2017 | ($22.35M) | Mar 13, 2019 |
| FY2018 | Dec 31, 2016 | ($23.69M) | Mar 13, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $94.0K | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $63.0K | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $45.0K | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | $120.0K | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $596.0K | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $884.0K | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | $475.0K | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $119.0K | Mar 20, 2020 |
| FY2018 | Dec 31, 2017 | $35.0K | Mar 13, 2019 |
| FY2018 | Dec 31, 2016 | $271.0K | Mar 13, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $209.47M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $181.45M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $78.95M | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | $113.29M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $172.60M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $203.16M | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | $1.22M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $23.52M | Mar 20, 2020 |
| FY2018 | Dec 31, 2017 | $43.98M | Mar 13, 2019 |
| FY2017 | Dec 31, 2016 | $43.52M | Mar 14, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.06M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $14.32M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $10.63M | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | $11.21M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $10.68M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $3.91M | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | $3.35M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $3.08M | Mar 20, 2020 |
| FY2018 | Dec 31, 2017 | $9.24M | Mar 13, 2019 |
| FY2017 | Dec 31, 2016 | $5.08M | Mar 14, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $196.41M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $167.13M | Mar 10, 2026 |
| FY2025 | Dec 31, 2023 | $68.32M | Mar 10, 2026 |
| FY2024 | Dec 31, 2022 | $102.08M | Mar 5, 2025 |
| FY2023 | Dec 31, 2021 | $161.91M | Mar 13, 2024 |
| FY2022 | Dec 31, 2020 | $199.24M | Mar 8, 2023 |
| FY2021 | Dec 31, 2019 | ($2.13M) | Mar 9, 2022 |
| FY2020 | Dec 31, 2018 | $4.78M | Mar 11, 2021 |
| FY2019 | Dec 31, 2017 | $34.74M | Mar 20, 2020 |
| FY2018 | Dec 31, 2016 | $38.44M | Mar 13, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2021 | $29.52M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $29.52M | Mar 9, 2022 |
| FY2022 | Jan 9, 2020 | $29.50M | Mar 8, 2023 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($302.42M) | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | ($244.98M) | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | ($200.38M) | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | ($159.96M) | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | ($94.01M) | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | ($46.76M) | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | ($12.78M) | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | ($210.47M) | Mar 20, 2020 |
| FY2018 | Dec 31, 2017 | ($189.74M) | Mar 13, 2019 |
| FY2017 | Dec 31, 2016 | ($159.78M) | Mar 14, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $49.66M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $162.80M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $39.59M | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | $24.13M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $35.72M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $168.60M | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | $564.0K | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $19.37M | Mar 20, 2020 |
| FY2018 | Dec 31, 2017 | $21.17M | Mar 13, 2019 |
| FY2017 | Dec 31, 2016 | $36.39M | Mar 14, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | (3) | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | (5) | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | (4) | Mar 8, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | (3) | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | (5) | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | (4) | Mar 8, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 53.59M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | 35.04M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | 11.36M | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | 11.27M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | 11.24M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | 11.21M | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | 2.63M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | 481,091 | Mar 20, 2020 |
| FY2018 | Dec 31, 2017 | 17.67M | Mar 13, 2019 |
| FY2017 | Dec 31, 2016 | 16.60M | Mar 14, 2018 |